Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

BHVN has been the subject of several other reports. Morgan Stanley began coverage on Biohaven Pharmaceutical Holding Co in a report on Wednesday, May 31st. They issued an “overweight” rating for the company. Needham & Company LLC began coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued a “buy” rating and a $30.00 target price for the company. Piper Jaffray Companies began coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued an “overweight” rating and a $21.00 target price for the company. William Blair began coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued an “outperform” rating and a $46.00 target price for the company. Finally, Barclays PLC began coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued an “overweight” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $31.75.

Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) traded up 9.64% during mid-day trading on Monday, hitting $37.54. 241,501 shares of the stock traded hands. Biohaven Pharmaceutical Holding Co has a 1-year low of $17.00 and a 1-year high of $38.00. The firm’s market capitalization is $1.35 billion. The company has a 50-day moving average of $25.97 and a 200 day moving average of $24.54.

COPYRIGHT VIOLATION NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Upgraded to Hold by Zacks Investment Research” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/28/biohaven-pharmaceutical-holding-co-ltd-bhvn-upgraded-to-hold-by-zacks-investment-research.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.